DEF 14A: GRI Bio Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

GRI Bio is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing.

Summary

• GRI Bio is holding a special meeting on June 7, 2024, to seek stockholder approval for two proposals.
• The first proposal involves amending the company's certificate of incorporation to effect a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-15.
• The exact ratio will be determined by the board of directors.
• The second proposal seeks approval to adjourn the special meeting if there are insufficient votes for the first proposal.
• The company needs to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• A reverse stock split is intended to increase the stock price.
• The company also needs to meet Nasdaq's minimum stockholders' equity requirement and may need to raise additional capital.
• If the reverse stock split is approved and implemented, the number of outstanding shares will decrease, but the total authorized shares will remain the same.
• Stockholders may receive cash in lieu of fractional shares resulting from the split.
• The board of directors recommends voting for both proposals.

Sentiment

Score: 4

Explanation: The document outlines a challenging situation for the company, requiring a reverse stock split to maintain Nasdaq listing and potentially needing further capital raising. While the company is taking action, the overall tone reflects financial difficulties and uncertainty.

Positives

• A reverse stock split could increase the market price of the common stock, potentially helping the company regain compliance with Nasdaq listing requirements.
• The company has the flexibility to abandon the reverse stock split if the stock price recovers sufficiently.
• The company believes that a higher stock price could improve marketability to institutional investors and other members of the investing public.
• The company has the ability to adjourn the special meeting to solicit additional proxies if needed.

Negatives

• Reverse stock splits can have a negative perception among investors.
• There is no guarantee that the reverse stock split will increase the stock price or maintain it above $1.00.
• The company may still need to raise substantial additional funds to meet Nasdaq's stockholders' equity requirement.
• If the company is delisted from Nasdaq, trading of its common stock would be conducted on the OTC Markets or the pink sheets, making it more difficult for investors to dispose of or obtain accurate quotations.
• The company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets, delay, scale back, or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose, or cease operations entirely if it is unable to secure adequate additional funding when needed.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price and stockholders' equity requirements could result in delisting.
• The reverse stock split may not increase the stock price as intended.
• The company may not be able to secure additional funding when needed.
• Delisting from Nasdaq could make it more difficult for investors to trade the company's stock.
• The issuance of additional shares could dilute existing stockholders and cause a decline in the trading price of the common stock.

Future Outlook

The company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements. The company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2024.

Management Comments

• The board of directors believes that if the number of shares of our common stock cast at the Special Meeting is insufficient to approve the Amendment Proposal, it is in the best interests of our stockholders to enable our board of directors to continue to seek to obtain a sufficient number of additional votes to approve the Amendment Proposal.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Many biotech companies in similar situations have pursued reverse stock splits to maintain their listing and attract institutional investors.

Comparison to Industry Standards

• Many companies facing Nasdaq delisting due to low share prices consider reverse stock splits.
• For example, companies like XOMA Corporation and BioSpecifics Technologies Corp. have previously implemented reverse stock splits to regain compliance with Nasdaq listing requirements.
• The success of a reverse stock split in maintaining listing and improving investor perception varies widely and depends on the company's underlying financial performance and market conditions.

Stakeholder Impact

• Shareholders may experience a change in the number of shares they own due to the reverse stock split.
• The reverse stock split could impact the market price of the company's stock.
• Employees may be affected by potential reductions in spending or scaling back of development programs.
• The company's ability to secure additional funding could impact its relationships with suppliers and creditors.

Next Steps

• Stockholders to vote on the Amendment Proposal and the Adjournment Proposal at the Special Meeting on June 7, 2024.
• Board of directors to determine the exact ratio of the reverse stock split if approved.
• Company to file a certificate of amendment with the Secretary of State of the State of Delaware if the reverse stock split is approved and implemented.
• Company to continue efforts to regain compliance with Nasdaq listing requirements.
• Company to seek additional funding through equity or debt financing.

Key Dates

Keywords

reverse stock split, Nasdaq, compliance, stockholders equity, minimum bid price, delisting, proxy statement, common stock, GRI Bio, Amendment Proposal, Adjournment Proposal